Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000723703 | SCV000110531 | pathogenic | not provided | 2013-09-19 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV000078672 | SCV000281793 | pathogenic | Severe early-childhood-onset retinal dystrophy | 2016-01-01 | criteria provided, single submitter | clinical testing | |
Blueprint Genetics | RCV001074239 | SCV001239812 | pathogenic | Retinal dystrophy | 2019-04-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000723703 | SCV001380886 | pathogenic | not provided | 2024-10-22 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 1 of the ABCA4 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ABCA4 are known to be pathogenic (PMID: 10958761, 24938718, 25312043, 26780318). This variant is present in population databases (rs398123339, gnomAD 0.0009%). Disruption of this splice site has been observed in individual(s) with Stargardt disease (PMID: 28559085; internal data). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 92871). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Institute of Medical Genetics and Applied Genomics, |
RCV000723703 | SCV001905563 | likely pathogenic | not provided | 2021-09-15 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV000078672 | SCV002072544 | pathogenic | Severe early-childhood-onset retinal dystrophy | 2022-06-23 | criteria provided, single submitter | clinical testing | This variant was identified as compound heterozygous with NM_000350.3:c.5603A>T._x000D_ Criteria applied: PVS1, PM3, PM2_SUP |
Institute of Human Genetics, |
RCV001074239 | SCV005072127 | pathogenic | Retinal dystrophy | 2018-01-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005025131 | SCV005656586 | likely pathogenic | Cone-rod dystrophy 3; Age related macular degeneration 2; Severe early-childhood-onset retinal dystrophy; Retinitis pigmentosa 19 | 2024-05-02 | criteria provided, single submitter | clinical testing | |
Centre for Mendelian Genomics, |
RCV000415227 | SCV000492545 | pathogenic | Visual impairment; Central scotoma; Macular degeneration; Retinal atrophy | 2016-06-12 | no assertion criteria provided | clinical testing |